Citius Pharmaceuticals, Inc. current report, 18 September 2014

Full document

Citius Pharmaceuticals, Inc. - Form 8-K Summary

Business Context and Reporting Period

Date: September 18, 2014
Event: Completion of a Reverse Acquisition and Private Offering.
Context: Trail One, Inc. (formerly a shell company manufacturing license plates) entered into a Share Exchange and Reorganization Agreement with Citius Pharmaceuticals, LLC. Effective September 12, 2014, Citius became a wholly-owned subsidiary, and the Company changed its name to Citius Pharmaceuticals, Inc. The Company is a specialty pharmaceutical firm focused on obesity and hemorrhoid treatments using the FDA's 505(b)(2) pathway.

Key Financial Metrics

Capital Raised (Private Offering): $2,040,000 gross proceeds from the sale of 3,400,067 Units at $0.60 per Unit.
Debt Conversion: Approximately $2,035,000 in convertible notes and subordinated notes, plus accrued interest, were converted into membership interests (later exchanged for common stock) in connection with the transaction.
Historical Performance (Citius LLC):

  • Revenue: $0 for the six months ended June 30, 2014, and full years 2013 and 2012.
  • Net Loss: $125,159 (6 months ended June 30, 2014); $1,288,003 (Year ended Dec 31, 2013); $1,049,425 (Year ended Dec 31, 2012).
  • Cash Flow: Net cash used in operations was $80,947 (6 months ended June 30, 2014).
  • Liquidity: As of June 30, 2014, Citius had a working capital deficit of $1,297,314 and an accumulated members' deficit of $2,976,913.
Capital Structure Post-Transaction: 30,025,286 shares of common stock outstanding. Citius stockholders own approximately 72.0% of the company.

Material Changes vs. Prior Period

  • Corporate Identity: Transitioned from a shell company (Trail One) to an operating pharmaceutical entity (Citius).
  • Management: Mohammad Omar Rahman (former CEO of Trail One) resigned. Leonard Mazur was appointed CEO, President, COO, and sole director.
  • Capitalization: Significant dilution occurred via the issuance of 21,625,219 shares to Citius stockholders and 3,400,067 shares to private investors. A reverse stock split (0.625:1) was executed prior to the acquisition.
  • Financial Status: The transaction resolved a significant working capital deficit and converted substantial debt obligations into equity, though the Company remains in a development stage with no revenue.

Guidance, Outlook, Risks, and Contingencies

Outlook: Management expects the proceeds from the Private Offering to fund operations for approximately 12 months. The Company plans to raise additional capital to fund clinical trials for its hemorrhoid candidate and long-term usage studies for its obesity product, Suprenza.
Going Concern: Auditors have issued a "going concern" opinion due to recurring losses and negative cash flows. There is substantial doubt about the ability to continue as a going concern without additional financing.
Key Risks:

  • Regulatory: Reliance on the 505(b)(2) pathway; potential delays or denials of FDA approval for new indications.
  • Intellectual Property: Ongoing patent litigation against Zydus Pharmaceuticals regarding generic versions of Suprenza. A 30-month stay on FDA approval of the generic is in effect, but settlement discussions are ongoing.
  • Market: Competition from established pharmaceutical companies and generic alternatives; dependence on third-party manufacturers and sales partners (Prenzamax/Akrimax).
  • Liquidity: If additional financing is not secured, development programs may be curtailed.
Unusual Items: The transaction involved a reverse acquisition, a reverse stock split, and the conversion of debt to equity. The Company is subject to "Penny Stock" rules.

Investor Verification Checklist

  • Capital Sufficiency: Verify if the $2.04M raised is sufficient to reach the next major milestone (Phase 2/3 trials) or if immediate follow-on financing is required.
  • Patent Litigation Status: Monitor the outcome of the lawsuit against Zydus Pharmaceuticals regarding the Suprenza patent (U.S. Patent No. 6,149,938) and the potential for a settlement.
  • Revenue Model: Confirm the terms of the profit-sharing agreement with Prenzamax LLC, as Citius currently records $0 revenue despite product sales by the partner.
  • Registration Rights: Verify the timeline for the filing of the Registration Statement for the resale of shares sold in the Private Offering (required within 60 days of closing).
  • Management Transition: Assess the experience of the new CEO, Leonard Mazur, and the composition of the new Board of Directors.